Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson's disease

Expert Opin Ther Targets. 2022 Jun;26(6):537-546. doi: 10.1080/14728222.2022.2082937. Epub 2022 Jun 2.

Abstract

Areas covered: In this review, we will provide an update on the current status of drugs and other technologies that have emerged in recent years and provide an overview of their efficacy in ameliorating LRRK2 kinase activity and overall safety in animal models and humans.

Expert opinion: The growth of both target discovery and innovative drug design has sparked a lot of excitement for the future of how we treat Parkinson's disease. Given the immense focus on LRRK2 as a therapeutic target, it is expected within the next decade to determine its therapeutic properties, or lack thereof, for PD.

Keywords: LRRK2; Leucine-rich repeat kinase 2; Parkinson’s disease; kinase inhibition.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Drug Design
  • Leucine / therapeutic use
  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 / genetics
  • Parkinson Disease* / drug therapy

Substances

  • Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
  • Leucine